ACLARION INC

Company Overview

Aclarion (formerly Nocimed) is a small healthcare‑technology company commercializing NOCISCAN, an MR spectroscopy (MRS) software suite intended to non‑invasively identify painful intervertebral discs to inform spine surgical and conservative care decisions. The initial commercial focus is the U.S. spine fusion market (~$10B) with longer‑term expansion across the broader low back/neck pain market; delivery depends on a four‑part workflow (scanner protocol, secure transfer, cloud post‑processing and clinician reports) and on partner integrations (notably Siemens, initial Philips work, RadNet). Revenues to date have been limited and largely out‑of‑pocket, with recent modest traction in the U.K.; operational constraints include a small installed base of compatible scanners, one‑time site costs, dependency on UCSF licensing and payer coverage conversion (Category III → Category I). The company is loss‑making, raised ~$20.1M in H1 2025 to extend runway into Q3 2026, and remains highly execution‑ and reimbursement‑risk dependent.

Executive Compensation Practices

Given the development‑stage profile and constrained cash, executive pay is likely weighted toward equity and milestone‑driven incentives rather than high cash salaries; management disclosures cite equity‑based compensation as a judgmental accounting area under ASC 718 and show bonus accruals as a material component of G&A. Pay packages are expected to emphasize commercialization and regulatory/reimbursement milestones (e.g., CPT code conversion, payer coverage wins, CLARITY trial enrollment/progress, scanner vendor integrations) plus IP/licensing targets tied to the UCSF agreement. Sales/marketing and commercial hires (regional market managers/KOL engagement) are major near‑term performance drivers, so short‑term bonuses or performance units may be linked to adoption metrics and partner rollouts, while long‑term equity (options/RSUs) will be used to conserve cash and align incentives. Compensation dilution risk is meaningful given ongoing financing needs, so equity grants and bonus settlements should be evaluated alongside share issuance and warrant activity.

Insider Trading Considerations

Material, market‑moving events for trading windows include payer coverage announcements (Category III → Category I progress), CLARITY trial milestones and enrollment updates, published clinical results, new scanner vendor integrations, and financing or settlement news; insiders will likely be subject to blackout periods around those events. Because the company is small, pre‑revenue and has a history of frequent financings and warrant/derivative adjustments, watch for insider sales tied to option exercises, financings, or liquidity needs—such transactions can be more likely and more impactful on a thin float. Expect insiders to rely on equity‑focused compensation and potentially establish 10b5‑1 plans; however, researchers should monitor timing relative to clinical/regulatory announcements, related‑party financings, and lock‑up expirations. Finally, regulatory and contractual constraints (FDA classification risk, UCSF license and vendor agreements) can create asymmetric information events that materially affect trading behavior and should be watched closely.